Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics CFO Jeffrey Rona steps down; Charles Carter named CFO

Neutral Impact 4 of 5 leadership Written later

Ovid Therapeutics said its Chief Business and Financial Officer, Jeffrey Rona, will leave the company effective July 6, 2026, by mutual agreement. The Board appointed Charles Carter, the company's Senior Vice President of Finance and Financial Planning, as Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective the same day. The company states the departure was not due to any disagreement on accounting, financial statements, internal controls, operations, policies or practices.

Key points

  • Jeffrey Rona's separation date is July 6, 2026; the 8-K says he agreed to leave by mutual agreement, not over any accounting or control disagreement.
  • Charles Carter, age 59, takes the CFO, principal accounting officer and secretary roles, having served as SVP of Finance and Financial Planning since October 2024.
  • Carter's pay includes a $460,000 base salary, a target bonus of 35% of base salary, a 50,000-share RSU award vesting in two annual installments from July 6, 2027, and a $75,000 bonus opportunity.
  • Rona will receive 12 months of base salary, a prorated 2026 bonus and up to 12 months of COBRA benefits, and will provide advisory services through December 31, 2027.

The filing

CompanyOvid Therapeutics Inc. (OVID)
Form8-K, current report
Filed with the SECJul 8, 2026, 7:03 AM ET
Accession number0001628280-26-047584

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.